Background: Diagnosis of chronic hepatitis C virus (HCV) infection requires both a positive HCV antibody screen and confirmatory nucleic acid testing (NAT). Testing for hepatitis C virus core antigen (HCVcAg) is a potential alternative to NAT.
A pproximately 130 to 150 million persons are infected with chronic hepatitis C virus (HCV) , and approximately 75% of all cases occur in low-and middleincome countries (LMICs) (1, 2) . Direct-acting antivirals allow safe and effective curative treatment, but treatment is the final step in a long cascade that requires screening, confirmation, notification of results, and linkage to care (3, 4) . Diagnosis of HCV is a 2-step process that starts with screening for exposure with an assay that detects antibodies to HCV (anti-HCV), followed by nucleic acid testing (NAT) for persons with reactive anti-HCV to confirm active viremia. Among those who acquire a primary infection, 15% to 50% will spontaneously clear the virus within the first 2 to 6 months and remain positive for anti-HCV, although they are not actively infected and do not require treatment (5) . The diagnostic process is designed to be cost-effective, with a low-cost screening test followed by targeted testing with the more expensive NAT. In LMICs, implementation of a complex algorithm is often not feasible and diagnostic capacity is low; as a result, fewer than 1% of patients are aware of their infection (6). In addition, a significant proportion of patients who test positive for anti-HCV do not receive diagnostic NAT and are lost to follow-up (7). The 2-step diagnostic process is a major bottleneck to the HCV cascade of care that needs to be addressed to achieve the ambitious elimination strategy proposed by the World Health Organization (WHO) (8) .
Testing for hepatitis C virus core antigen (HCVcAg) is a potential replacement for NAT. The HCVcAg forms the internal capsid, which is highly conserved and antigenic (9, 10) . During viral assembly, nucleocapsid peptide 22 is released into the plasma (11) and can be detected earlier than antibodies and throughout the course of infection (12). The following 5 tests for HCVcAg detection are commercially available: Abbott ARCHITECT HCV Ag, which is an automated chemiluminescent microparticle immunoassay; Fujirebio Lumipulse Ortho HCV Ag and Eiken Lumispot HCV Ag, which are similar automated chemiluminescent enzyme immunoassays available in Japan and China; Hunan Jynda Bioengineering Group HCV Ag enzyme-linked
Study Selection
Inclusion criteria were as follows: case-control, cross-sectional, cohort, or randomized trials; commercially available HCVcAg tests; commercially available NAT as the reference standard; whole blood, plasma, or serum specimens; and at least 10 independent clinically collected samples. Studies done using commercially prepared reference panel specimens, published in abstract form only, or presented as slides or posters were excluded.
We included articles that reported results from populations with any distribution of patient age, from any country, and in any screening setting (for example, hospital-or community-based). Although we were primarily interested in test performance among persons at risk for HCV and with known infection, we also included studies using specimens from healthy blood donors. Because the performance characteristics of NAT are very similar when HCV RNA levels are greater than 50 IU/mL, we accepted any of the following NAT techniques as the reference standard: polymerase chain reaction, branched-chain DNA, or transcription-mediated amplification. Tests were classified as either qualitative or quantitative.
Data Extraction and Quality Assessment
Two authors (J.M.F. and T.M.T.) independently assessed all studies for inclusion and extracted data on study methods, characteristics, and test accuracy using a standardized extraction form (Supplement). Foreignlanguage studies were translated and extracted by native speakers using the same form. We crosschecked data points for 25% of the included studies. Disagreements between reviewers were resolved by discussion or by a third reviewer (C.M.D.). When elements for extraction were missing, we contacted the authors to request further data. We also requested individual specimen data to allow for a quantitative assessment of HCVcAg against HCV RNA. Studies without extractable sensitivity and specificity data were excluded if no further information was acquired after 3 attempts to contact the study authors.
Methodological quality of the included studies was assessed using a validated QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies) tool (19) . Details of the QUADAS-2 questions and interpretation are reported in the Supplement.
Data Synthesis and Analysis
We defined HCVcAg sensitivity as the proportion of samples with a positive NAT result that was also positive for HCVcAg. We defined HCVcAg specificity as the proportion of samples with a negative NAT result that was also negative for HCVcAg. Sensitivity and specificity were the primary outcome measures. Positive and negative likelihood ratios were calculated when pooled sensitivity and specificity data were available from meta-analysis. Indeterminate test results accounted for fewer than 1% for all index tests and were excluded from further analyses.
We constructed forest plots for each HCVcAg index test to visually assess heterogeneity by examining the CIs of individual studies. We then used summary plots to examine the width of the prediction region, with a wider prediction region suggesting more heterogeneity. When at least 4 studies with limited heterogeneity were available, we used a bivariate random-effects model and carried out meta-analyses using the metandi command in STATA, version 14 (StataCorp) (20, 21) .
When at least 4 studies provided sensitivity data only, we did a univariate random-effects meta-analysis on the sensitivities to use all available data. Results from the univariate analyses (including all studies) were compared with the pooled estimates from the bivariate analyses where possible. Descriptive analyses were done for index tests with fewer than 4 studies and when substantial heterogeneity was evident from inspection of the forest and summary plots.
When quantitative data were available, a locally weighted regression smoother was used to visually assess the linearity of quantitative HCVcAg (measured in fmol/L) to HCV RNA (measured in IU/mL) (22) . We identified outliers and recorded descriptive statistics of these points. Quantitative data were insufficient to assess any test other than Abbott ARCHITECT.
We assessed for publication bias when more than 10 studies were available for an index test. We generated funnel plots displaying the log diagnostic odds ratio versus the SE for each study (18). We also did the trim-and-fill statistical assessment in STATA using the metatrim command (23) . Unpublished data were not included. All statistical analyses were done using STATA and R, version 3.2.5 (R Foundation for Statistical Computing).
Role of the Funding Source
This systematic review was supported by the National Institutes of Health, which had no direct involvement in the study design, collection, analysis, or interpretation of the data or in the decision to submit the manuscript for publication.
RESULTS

Study Selection and Characteristics
The systematic review identified 8508 citations, from which we reviewed 299 full-text articles and identified 44 that met the a priori-defined inclusion criteria (Appendix Figure 1 , available at www.annals.org). Of the included studies, 44 used the 5 HCVcAg assays; 1 of these studies directly compared 3 antigen tests. Four studies were translated from Mandarin (24 -27), 1 from German (28), and 2 from Japanese (29, 30) . Characteristics for each study are presented in Table 1 .
Risk-of-Bias Assessment
The overall risk-of-bias assessment for all included studies across each QUADAS-2 domain is summarized in Appendix Figure 2 and presented for each study by index test in Appendix Figure 3 (both figures available at www.annals.org). Studies using Abbott ARCHITECT had the highest quality. However, 15 of the 33 studies did not report on whether patients were recruited consecutively and 1 included only healthy blood donors (31) . The 6 studies using the Ortho ELISA had the lowest quality; 2 did not report patient selection methods (32, 33) , and only 1 included healthy blood donors (34) . In addition, 2 studies did convenience sampling (29, 30) and it was unclear in both studies whether the index test and reference tests were performed on the same sample or within 30 days in the same participant and whether the index test was performed in accordance with manufacturer recommendations. For the Hunan Jynda ELISA, patient selection was unclear in 1 study (25) , timing of the index and reference tests was unclear in 1 study (26) , and only healthy blood donors were enrolled in 1 study (35) . For Eiken Lumispot, both studies had unclear participant selection (36, 37) , as did the study that assessed Fujirebio Lumipulse (37) .
HCVcAg Assays for Diagnosis of Active HCV Infection
Abbott ARCHITECT
We found 33 studies assessing Abbott ARCHITECT (11, 24, 28, 31, . All were either cross-sectional or cohort designs with a broad study population (they included patients with HCV infection and those susceptible to HCV infection), except for 1 study that evaluated only healthy blood donors (31) . Demographic data were available in 21 studies; the remainder used anonymous specimens, and the authors could not provide further information. HIV status was known in 16 studies, with 3 including only persons with HIV coinfection (59, 61, 64) . Hepatitis B virus (HBV) status was known in 13 studies, and all but 4 excluded patients with HBV co-infection. The highest prevalence of HBV co-infection (defined as hepatitis B surface Ag positivity) was 50.5% (53) . Only 1 study included children (43) .
The bivariate analysis consisted of 23 studies. The 10 remaining studies (11, 37, 40 -42, 49, 52, 56, 60, 62) did not have data to calculate specificity and were only included in the pooled sensitivity estimate from the univariate analysis. For the bivariate analysis, there were 12 670 total samples. The pooled sensitivity and specificity, regardless of anti-HCV status, were 93.4% (95% CI, 90.1% to 96.4%) and 98.8% (CI, 97.4% to 99.5%), respectively. The positive and negative likelihood ratios were 80.6 (CI, 36.4 to 178.8) and 0.06 (CI, 0.04 to 0.1), respectively (Table 2; Figure 1 ; and Appendix Figure 4 , available at www.annals.org). The pooled sensitivity estimate from the univariate analysis, including the 10 additional studies (total of 13 638 samples), was similar to that of the bivariate analysis-94.3% (CI, 92.8% to 95.9%) ( Table 2 and Appendix Figure 5 , available at www.annals.org)-although the estimate was higher among the 10 studies when evaluated alone (99% [CI, 97.8% to 100%]). Among 16 studies with known anti-HCV-positive samples, sensitivity was 92.5% (CI, 86.9% to 95.8%) and specificity was 97.8% (CI, 94.7% to 99.1%) ( Table 2 and Appendix Figure 6 , available at www.annals.org). In the 5 studies that analyzed anti-HCV-negative samples in the acute or preseroconversion phase, the pooled sensitivity was lower, with a wide CI (92.3% [CI, 3.7% to 99.9%]). Specificity among anti-HCV-negative samples remained high at 98.8% (CI, 97.3% to 99.4%) ( Table 2 and Appendix Figure 7 , available at www.annals.org).
Heterogeneity was visually assessed in Figure 1 and Appendix Figures 4 to 7. The studies seem to be homogeneous in the overall bivariate analysis, except for 1 outlier study (24) that had no demographic information to perform further analysis. Overall, genotype distribution was reported for 18 studies (Appendix Ta-ble, available at www.annals.org), with genotype 1b being the most prevalent and genotypes 5 and 6 only minimally studied. In the univariate analysis, there were 3 outlier studies (24, 43, 44) . In the study by Ergü nay and colleagues (43) from Turkey, the status of HIV and HBV co-infection was unknown and genotype distribution was similar overall to other studies that reported data: 60.2% of participants had HCV genotype 1b infection, 2.2% had genotype 1a, 0.8% had genotypes 3 and 4, and 35.8% were unknown (Appendix Table) . In the study by Florea and colleagues (44) from Romania, no patients had HIV or HBV infection and the HCV genotype was unknown. For specificity, the results were even more homogeneous with only 1 outlier-the study by Medici and colleagues (54) from Italy and Spain that reported 63 false-positive test results. This study had no 
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The funnel plot of the log diagnostic odds ratio versus SE for all 33 included studies was symmetrical (Appendix Figure 8 , available at www.annals.org), which suggested low publication bias. This was further supported by the trim-and-fill statistical test, which found no change in heterogeneity between the random-effects model and a filled model (data not shown).
The Ortho ELISA
Six studies used the Ortho ELISA (29, 30, (32) (33) (34) 66) . All were either cross-sectional or cohort designs in general study populations, except for 1 study done in healthy blood donors (34) . All had unknown demographic information.
Five studies were included in the bivariate analysis with 1177 total samples. Pooled sensitivity and specificity, regardless of anti-HCV status, were 93.2% (CI, Table 2 ). In the summary plot, the summary point was approaching the upper-left corner, which suggests good accuracy of the Ortho ELISA for diagnosis of active HCV infection. However, these data exhibited some heterogeneity given the wide CIs (Appendix Ag = antigen; ELISA = enzyme-linked immunosorbent assay; HCV = hepatitis C virus; HCVcAg = hepatitis C virus core antigen; NA = not applicable; NAT = nucleic acid testing; ND = no data. * Results from bivariate and univariate analyses, range of studies, and single studies are reported. Bivariate and univariate meta-analyses were done using the "metandi" and "metan" commands in Stata, respectively. † If sensitivity and specificity results were NA from meta-analysis, likelihood ratios were not calculated. ‡ Meta-analysis was not possible; the range of results seen across studies was reported. 
Sensitivity Specificity
Abbott ARCHITECT = Abbott ARCHITECT HCV Ag assay; Ag = antigen; anti-HCV = antibody to hepatitis C virus; HCV = hepatitis C virus; NAT = nucleic acid testing. Table) . Further, this study was performed in 494 plasma samples collected from only 52 donors at various time points during HCV infection, and thus the samples did not provide independent data points. Raw quantitative data were not available.
Eiken Lumispot
The Eiken Lumispot was used in 1 cross-sectional study of a general study population (36) . Further demographic information was unavailable. Eiken Lumispot, Fujirebio Lumipulse, and Abbott ARCHITECT were compared in 1 cross-sectional study (37) with unknown demographic information.
The first study included 155 samples, and the sensitivity reported was 98.1% (CI, 95.9% to 100%) ( Table  2 ) (36) . Most samples were HCV genotype 1 (65.2%), and the remaining were HCV genotype 2. The second study comparing 3 assays (37) included 80 participants and reported a sensitivity of 97.5% (CI, 94.1% to 100%) for Eiken Lumispot. Data were insufficient to determine specificity in either study.
Fujirebio Lumipulse
One study was done using Fujirebio Lumipulse with 80 participants (37) . Sensitivity for this test was reported as 95.0% (CI, 90.2% to 99.8%) ( Table 2) . Data were insufficient to determine specificity.
Hunan Jynda ELISA
Four studies assessed the Hunan Jynda ELISA (25) (26) (27) 35) . Two studies had a cohort or cross-sectional design. One assessed a population of healthy blood donors (35) , whereas the others included broad study populations. HIV and HBV co-infection status were unknown in all studies. One study included children (27) , and the age groups for the remaining studies were unknown.
All 4 studies were included in the bivariate analysis with 562 total samples. Pooled sensitivity and specificity were 59.5% (CI, 46.0% to 71.7%) and 82.9% (CI, 58.6% to 94.3%), respectively. Positive and negative likelihood ratios were 3.5 (CI, 1.1 to 12.6) and 0.28 (CI, 0.2 to 0.3), respectively ( Table 2) . Both the forest plot (Appendix Figure 11 , available at www.annals.org) and bivariate analysis (Appendix Figure 12 , available at www.annals.org) showed heterogeneity among the 4 studies, which limited confidence in the pooled estimate. No covariate assessment was done because HIV status, HBV status, and genotype distribution were unknown for all studies.
Quantitative Data
Three studies provided quantitative data for analysis (48, 54, 57) . All used Abbott ARCHITECT in comparison with NAT. Of note, there were 90 anti-HCVpositive specimens in the study by Kadkhoda and Smart (48) , 205 anti-HCV-positive and 77 anti-HCVnegative specimens in the study by Park and coworkers (57) , and 1152 anti-HCV-positive specimens in the study by Medici and colleagues (54) . The HCVcAg was shown to correlate well with RNA, except when levels were less than 3000 IU/mL, which yielded negative HCVcAg test results (Figure 2 ). In the study by Kadkhoda and Smart, among the 8 specimens with HCV RNA levels greater than 3000 IU/mL and negative HCVcAg test results, the genotype distribution among participants was similar to the cohort as a whole (12.5% unspecified, 37.5% genotype 1, 25% genotype 2, and 25% genotype 3). No genotype or co-infection information was available for the specimens in the studies by Park and coworkers or Medici and colleagues to further characterize outlier points.
DISCUSSION
This systematic review concludes that a wellperforming HCVcAg test can achieve similar diagnostic accuracy to NAT for identification of active HCV infection when the viral load exceeds 3000 IU/mL. Both Abbott ARCHITECT and the Ortho 100%] ). However, the large amount of consistent, homogenous data on Abbott ARCHITECT (33 studies vs. 6 on the Ortho ELISA) allows for greater precision and more confidence in these estimates. The likelihood ratios for both tests are also very favorable and allow for clinical decision making based on test results. The Eiken Lumispot and Fujirebio Lumipulse were designed with the same principle technology as Abbott ARCHITECT and have similar sensitivity and specificity, although assessment was limited to 1 and 2 studies, respectively. However, our systematic review included Chinese and Japanese literature. Such tests as the Hunan Jynda ELISA have the lowest sensitivity (59.5% [CI, 46.0% to 71.7%]), which supports the notion that an ELISA is insufficient for detection and that signal amplification (as with chemiluminescence) is necessary to achieve adequate detection limits.
We searched PubMed on 31 March 2016 for recent reviews of HCVcAg and retrieved 1 systematic review done in 2012 (67) . Our study adds to this review because we included many studies published since 2012 and eliminated those that used HCVcAg tests that are no longer commercially available. The analysis differs because we evaluated the performance of each commercial test separately, rather than pooling all HCVcAg tests into 1 multivariate random-effects model. Our results allow indirect between-test comparisons and avoid the problematic heterogeneity introduced by pooling performance characteristics of different detection technologies. We also searched ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform, but we did not find any active studies investigating HCVcAg.
Strengths of this review include the development of an a priori protocol and analysis plan. The search was done without language restriction, although 3 articles were excluded because of inability to find translation for Russian, Korean, and Polish. Nevertheless, studies may have been missed and subsequent studies published after the search date could not be included. Article selection and standardized data extraction in accordance with the predefined protocol were ensured by independent reviewers. Authors were contacted to provide missing data and clarifications, and some studies were excluded because of lack of author response. In the analysis, bivariate random-effects modeling was used when appropriate to derive pooled estimates and univariate analyses were done in an effort to use all available data.
The data summarized in this review had limitations. We planned to examine the effects of HBV co-infection, HIV co-infection, and HCV genotype in a metaregression analysis, but this was not possible because of the limited data on these covariates. Data on HCVcAg test performance in genotypes 4, 5, and 6 are largely lacking, which limits the conclusions. In addition, a sensitivity analysis to examine the effect of the specimen condition (fresh vs. frozen) could not be done because all studies used frozen samples or did not specify the specimen condition. Not enough studies used Eiken Lumispot and Fujirebio Lumipulse to derive pooled estimates, and only descriptive analyses could be completed. Most of the studies were done in high-resource settings and reference laboratories. This might not reflect the population that would be tested if HCVcAg tests were implemented in LMICs, particularly given the limited data for genotypes 4, 5, and 6, which are more prevalent in such countries (68) .
The limitations highlight a need for better surveillance data to improve the understanding of how many patients are missed (false-negative test results) by assays that have greater limits of detection (for example, 3000 IU/mL for Abbott ARCHITECT) and whether covariates, such as HIV or HBV co-infection and HCV genotype, affect assay results. More information is needed about the fluctuation of RNA levels and HCVcAg during the preseroconversion phase, as well as for the rare patients with high viral loads who are negative for HCVcAg, to inform the optimization of antigen detection. This study focused only on the use of HCVcAg as a screening and diagnostic test, although NAT is also used in treatment monitoring and to assess sustained virologic response after therapy is completed. The performance of HCVcAg to confirm sustained virologic response at the completion of therapy should be further investigated. However, recent publications (69, 70) suggest that it may no longer be necessary to record viral load measurements of patients receiving directacting antivirals.
For both HCVcAg tests and NAT to reach a larger population at risk in LMICs, tests with better POC suitability need to be developed or transport mechanisms with dried blood spots need to be improved to enable better centralized testing depending on local settings. For any HCVcAg POC test, careful sample processing is necessary to lyse viral particles, expose the antigen, and dissociate the antibody from antigen to optimize detection. Signal amplification will be necessary to achieve sufficient sensitivity (as suggested by this review); therefore, an instrument-free assay (for example, a lateral-flow assay) is unlikely to be feasible in the near future. The cost of testing to the patient or health care provider is also a key factor for implementation in LMICs. The cost estimates from LMICs are highly variable and often country-specific, although cost estimates for HCVcAg tests are generally lower (from $10 to $50) than those for HCV RNA tests ($13 to $100) ( In summary, this systematic review showed that several HCVcAg assays are highly sensitive (>90%) and specific (>98%). Although even tests with the highest performance are not as sensitive as NAT, wellperforming HCVcAg tests with an analytic sensitivity reaching into the femtomolar range (equal to 3000 IU/ mL) could replace NAT for HCV detection, particularly if a lower cost per test allows more patients to be served. Therefore, HCVcAg should be explored for POC testing to increase the number of patients diagnosed and streamline the HCV cascade of care. 
